Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 28, 2013

OncoGenex begins enrolment in Rainier Phase II pancreatic cancer trial

OncoGenex Pharmaceuticals has started enrolment in the investigator-sponsored Rainier Phase II trial of apatorsen (OGX-427) in combination with Abraxane plus gemcitabine in patients with metastatic pancreatic cancer.

Pancreas_cancer

OncoGenex Pharmaceuticals has started enrolment in the investigator-sponsored Rainier Phase II trial of apatorsen (OGX-427) in combination with Abraxane plus gemcitabine in patients with metastatic pancreatic cancer.

The placebo-controlled trial, sponsored by the Sarah Cannon Research Institute (SCRI), will randomise around 130 patients with either apatorsen, paclitaxel protein-bound particles for injectable suspension, or placebo in combination with Abraxane and gemcitabine therapy.

Overall survival (OS) is the primary objective of the study, which is designed to further evaluate progression-free survival (PFS), tumour response rates, safety, tolerability, and the effect of therapy on heat shock protein 27 (Hsp27) levels.

Sarah Cannon Research Institute (SCRI) GI cancer research program director Dr Johanna Bendell said median survival for patients with advanced pancreatic cancer remains low and the institute needs to explore additional strategies to address treatment resistance.

"We are very excited to open enrolment in the Rainier trial, to explore the role of Hsp27 in pancreatic cancer and to evaluate for the potential ability of apatorsen to improve clinical outcomes for patients when added to combination chemotherapy," Bendell said.

Conducted at approximately 12 sites in the US, Rainier is part of the ongoing studies evaluating treatment resistance in cancer (ORCA) programme encompassing clinical trials of apatorsen.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

A once-weekly intravenous (IV) experimental drug, apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells’ defenses and overcome treatment resistance.


Image: Micrograph of the most common type of pancreatic cancer. H&E stain. Photo: courtesy of KGH.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU